anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antiallergic composition and a bleaching composition each containing a lactobacillus fermentation extract obtained by fermenting a raw material, i.e. beans, rooibos tea or rose.  &lt;P&gt;SOLUTION: The antiallergic composition contains a lactobacillus fermentation composition that is obtained by inoculating lactobacillus into a medium containing at least one of soybean, red bean and rooibos tea followed by fermentation culture thereof. The bleaching composition contains a lactobacillus fermentation composition that is obtained by inoculating lactobacillus belonging to the genus Lactobacillus into a medium containing at least one of rooibos tea and rose followed by fermentation culture thereof, or contains a lactobacillus fermentation composition that is obtained by inoculating lactobacillus belonging to the genus Leuconostoc or Lactobacillus casei subsp. casei into a medium containing soybean followed by fermentation culture thereof. The antiallergic composition and the bleaching composition are enhanced in antiallergic effect and bleaching effect respectively owing to the corresponding lactobacillus fermentation composition.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A capsule for therapeutically active substances has a wall which is of a material soluble in the stomach or intestine, e.g. gelatine. The capsule is closed by a cover and forms a holder for the therapeutical material; the interior being divided by &gt;=1 partition into &gt;=2 or more compartments. The separate compartments may contain similarly active therapeutical substances or alternatively, the medicaments contained may differ in their effect. The solubility of the materials of the outer capsule and of the covers is different. Alternatively the speed at which the material dissolve may be the same. The contents of the separate compartments may be the same in quantity or they may be different. The capsule allows the same or differing materials to be released into the alimentary duct, at different intervals of time in the same or in widely differing quantities.
This application discloses a treatment support system making it easy for a physician in charge to ask another specialist physician, especially another expert physician, for an opinion. The support system is much useful in providing an optimal treatment for an emergency disease, reviewing an expert-physician&#39;s opinion. The support system comprises a database server including an expert-physician database file in which information of expert-physicians belonging to institutions other than the hospital is recorded, a primary terminal handled by a physician in charge of treating the emergency patient in the hospital, secondary terminals handled by expert-physicians, a primary transmitter for transmitting an initial disease data to each secondary terminal, a received information displayer to display the initial disease data on each secondary terminal, a secondary transmitter to transmit an opinion to the primary terminal, an opinion displayer to display the opinion on the primary terminal, and an alarmer to generate an alarm by sound, light, vibration or any combination thereof to each expert-physician when the initial disease data is transmitted to each secondary terminal. The initial disease data includes a disease image of the emergency patient and time when the image was taken. The opinion is concerning to necessity of an additional test and investigation for the emergency patient, a diagnosis for the emergency patient, or a treatment plan for the emergency patient. The primary transmitter transmits the initial disease data with a time period for transmitting the opinion.
1442568 Pepsin inhibition NATIONAL STARCH &amp; CHEMICAL CORP 22 Oct 1974 [23 Oct 1973] 45565/74 Heading C3H [Also in Division A5] The action of pepsin in aqueous solution at a pH not exceeding 5 is inhibited by watersoluble, sulphonated homo- and co-polymers of styrene in acid or salt form, wherein the watersoluble polymer has an average molecular weight of at least 600 and a degree of substitution of from 0À7 to 1À3 sulphonate groups per unit of styrene. The sodium, potassium, calcium, ammonium and tetramethylammonium salts are mentioned. The co-polymerizable monomer may be methyl methacrylate, maleic acid, acrylic acid or methyl styrene. The pepsininhibitory polymers may be formulated with conventional pharmaceutical ingredients (specified) in tablets, pills, capsules or elixirs for use in the treatment of peptic ulcers in human beings and animals. Dosages of 0À02-1À0 gram of the polymer may be administered orally to subject human beings. Examples demonstrate the inhibitory effects of the following: sulphonated polystyrene sodium salts of molecular weights ranging from 1600 to 7,000,000 and a degree of substitution of 1À0; sulphonated polystyrene ammonium salts of MW 600 and 10,000 and DS 1À0 and 1À2, respectively; copolymer of 70% styrene/30% methyl methacrylate sulphonated to a DS of 0À7 and of MW 400,000; and, for comparison, amylopectin sulphate of MW 60 million and DS 1À5. In certain cases, the polymers of low molecular weight had first been dialysed against distilled water and freezedried before use.
NEW MATERIAL:A fraction separated from a cultured product of a mold belonging to Monascus genus and having the following physical and chemical properties. Column chromatography, eluted at the eluting position of a neutral amino acid standard when adsorbed to a strongly acidic cation exchange resin column equilibrated with 0.2M pyridine-acetic acid buffer solution of 3.1 pH and eluted with 0.4M pyridine-acetic acid buffer solution of 4.6 pH; solubility, soluble in water, methanol, acetone, etc., and insoluble in n-butanol, chloroform, etc.; nature and appearance, highly viscous liquid having brown color; molecular weight, &lt;=3,000 by gel-filtration; color reaction, positive to ninhydrin reaction and Folin reaction. USE:A hypotensor. PREPARATION:For example, Monascus pilosus (IFO 4520) is inoculated in steamed rice, cultured and dried to obtain monascus. The monascus is extracted with ethanol, the extract is dissolved in 28% aqueous solution of acetic acid and the solution is passed through a strongly acidic cation exchange resin column. The adsorbed component is eluted to obtain the objective novel fraction.
1. Method in preparation of a medicament for preventing progression of atherosclerosis in a mammal, of an aliquot of the mammal&#39;s blood which has been subjected extracorporeally to an electromagnetic emission and an oxidative environment. 2. Method according to claim 1, wherein the oxidative environment comprises applying an oxidizing agent to the aliquot. 3. Method according to claim 2, wherein the oxidizing agent contains ozone gas, and the ozone gas is introduced into the blood aliquot in an amount which does not give rise to excessive levels of mutagenicity. 4. Method according to claim 2, wherein the oxidizing agent comprises a mixture of ozone gas and medical grade oxygen, the ozone gas being contained in the mixture in a concentration of up to about 300 mug/ml. 5. Method according to claim 4, wherein the ozone has is contained in the mixture in a concentration of up to about 30 mug/ml. 6. Method according to claim 4, wherein the mixture is applied to the aliquot at a flow rate of up to about 0.33 litres/min. 7. Method according to claim 1, wherein the electromagnetic emission comprises ultraviolet light having one or more UV-C band wavelengths. 8. Use according to claim 1, wherein the aliquot is further subjected to a temperature stressor, said temperature stressor comprising a temperature above or below body temperature which does not result in substantial hemolysis of the blood is the aliquot. 9. Use according to claim 8, wherein the temperature stressor is applied so that the temperature of at least part of the aliquot is in the range of from about 5 degree C to about 55 degree C. 10. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of tom about 37 degree C to about 44 degree C. 11. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of from about 0 degree C to about 36.5 degree C. 12. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of from about 10 degree C to about 30 degree C. 13. Use according to claim 9, wherein the mean temperature of the blood in the aliquot is in the range of from about 37 degree C to about 55 degree C. 14. Use according to claim 13, wherein the temperature is 42.5 +- 1 degree C. 15. Use according to claim 1, wherein the aliquot has a volume of up to about 400 ml. 16. Use according to claim 15, wherein the volume of the aliquot is about 10 ml. 17. Use according to claim 1, wherein the aliquot is subjected to the electromagnetic emission and the oxidative environment for a period of up to about 60 minutes. 18. Use according to claim 17, wherein the aliquot is subjected to the electromagnetic emission and the oxidative environment for a period of about 3 minutes. 19. Use according to claim 8, wherein the aliquot is simultaneously subjected to the electromagnetic emission, the oxidative environment and the temperature stressor. 20. Use according to claim 1, wherein the aliquot is simultaneously subjected to the electromagnetic emission and the oxidative environment.
The invention discloses a traditional Chinese medicine compound and lung health hot compress patch for relieving chronic obstructive emphysema, which is easy to enter skin striae and acupoints, then enter Sun Mai and collaterals, further enter meridians, move along with qi and blood, reach viscera and spread on the whole body, and can play a role in regulating functions of the acupoints of meridians on human bodies. According to the principle of &#39; external treatment, i.e. internal treatment &#39;, the external treatment herbs, i.e. internal treatment herbs &#39;, take full advantage of the effects of clearing lung-heat, resolving phlegm, dispersing lung-qi, relieving asthma, tonifying lung, regulating spleen and tonifying kidney. After being heated, the smell enters the skin striae and acupoints, then enters Sun Mai and collaterals, and enters meridians, which run along with qi and blood, reach viscera and spread throughout the body, and play a role in regulating the human body by the acupoints of the meridians. Can achieve the effects of clearing lung-heat, resolving phlegm, purifying lung, relieving asthma, tonifying lung, regulating spleen, tonifying kidney and the like.
It is an object of the present invention to provide in vivo analytical methods that allow for diagnosis and management of therapy for diseases involving discrete biochemical pathways. In the method of the invention, a labelled tracer probe, a specifically designed substrate of a &#34;gateway&#34; enzyme, an enzyme marking a regulatory point in a discrete biochemical pathway, is administered to a subject; a labelled product of the action of the enzyme is measured; and the appearance and concentration of the product are related to the disease condition of interest. Determination of the rate of substrate-product conversion of the gateway enzyme allows for the analysis to be made.  The method involves administering a defined amount of a labelled &#34;metaprobe&#34;  substrate of the gateway enzyme to a subject, at a site that provides access to a desired pool of the gateway enzyme in the subject, and measuring the amount of the chosen labelled product. The presence and amount of the chosen labelled product in, e.g., the breath, definitely indicates that the labelled metaprobe has been metabolized by the specific enzyme in the specific biochemical pathway under consideration, and from the calculated rate of substrate-product conversion by the gateway enzyme, the desired diagnostic determination may be made. Likewise, if a specific therapeutic treatment for a disease is underway with a patient, this method allows for a minimally invasive assessment of the effectiveness of the treatment, with minimal discomfort to the patient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing chondrosine, by which the chondrosine can simply and efficiently be produced from a chondroitin raw material in a high purity in a large amount and at a low cost.  &lt;P&gt;SOLUTION: This method for producing the chondrosine is characterized by hydrolyzing the chondroitin raw material and then subjecting the product to an electrodialysis. The chondroitin raw material is preferably selected from chondroitin, chondroitin sulfate, and a material having a chondroitin basic skeleton. The hydrolysis is an acid hydrolysis or an enzymatic hydrolysis. The electrodialysis is carried out using a membrane having a molecular weight cut off of 200 to 400.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
A pulmonary diagnostic apparatus includes a personal computer including a memory for storing expected values, each representing a predicted normal level for a pulmonary function. A parameter limit file stores abnormality limits, each related to one of the expected values. A configuration file contains a plurality of degree of severity labels and numerical breakpoints between severity degrees. Finally, a statement data file contains a plurality of textual statements concerning lung functions and diseases or conditions. The three files are operatively associated with the computer. Lung function measuring equipment also is connected to the computer, whereby measured values are compared with the expected values. Based on the comparison, the computer generates an output identifying certain measured values as abnormal, and the degree of abnormality. Also, appropriate statements from the statement data file are generated as output, based upon the comparison. By selectively editing the parameter limit, configuration and statement files, the operator can cause the computer to generate an output corresponding to the operator&#39;s preferred analytical approach and syntax.
The present invention pertains to medical techniques and can be used as a means for preventing and treating short respiratory failure, e.g. snoring, or as a means for progressively administering drugs in a dosed manner through the mouth during the sleep or awakening periods. The purpose of this invention is to increase the functional capacity of the device and to improve comfort during application, wherein said invention increases the range of potential applications of said device and improves its convenience of use. This invention essentially relates to a universal device for preventing and treating respiratory failure, for and administering drugs progressively through the mouth and for curing snoring. This device includes a connection plate with a spring shoulder, a cup-shaped tongue fixator as well as inner and outer perforated limitation lobes. In other embodiments, the device of the present invention can be dismantled. The cup-shaped tongue fixator and the inner limitation lobe may also include means for progressively administering drugs in a dosed manner, whereby it is possible to sanitise the oral cavity and to introduce drugs into the patient&#39;s organism. This device can further be used as a cosmetic means.
NEW MATERIAL:A compound expressed by formula I [R&lt;1&gt; is H, benzoyl or (substituted) phenyl sulfonyl; n is 0-3; X is H, halogen or lower alkoxy; R&lt;2&gt; is expressed by formula II (R&lt;3&gt; is H or lower alkyl) or expressed by formula III]. EXAMPLE:Ethyl 4-[(thiazolidine-2-yl)methyl]phenoxy acetate. USE:Used as an antagonist against thromboxane A2. Said compound has low toxicity and is useful for remedy of cerebrovascular twitch after subarachnoid hemorrhage and following cerebral ischemia symptom or asthma, etc. PREPARATION:An alcoholic substance expressed by formula IV is made to an aldehyde substance expressed by formula V by chromate oxidation with chromate anhydride, etc. Then, the aldehyde substance is reacted with cisthiamine hydrochloride in a solvent such as water or water-containing methanol to afford the compound expressed by formula I having H as the group R&lt;1&gt;.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic formulated with a titanium oxide composition having high iridescent color, concretely a new titanium composition produced by coating a flaky substrate with a titanium composition and peeling the applied titanium composition and a cosmetic formulated with the new titanium composition.  &lt;P&gt;SOLUTION: A titanium oxide having high iridescent color is used as the cosmetic. The titanium oxide is composed of a peeled composition produced by forming a coating layer of a titanium composition having a thickness of 0.05-0.6μm on the surface of a flaky substrate having a size of 50-800μm and peeling the coating layer of the titanium composition to form the coating layer composition. The flaky substrate is selected from natural mica, synthetic mica, glass flake, silica flake, alumina flake and barium sulfate and contains titanium oxide and/or titanium hydroxide in an amount of 70-99 wt.%. The cosmetic further contains 1-20 wt.% reinforcing agent composed of the oxide or hydroxide of one or more metals selected from iron, zinc, cobalt, nickel, lithium, sodium, bismuth, tungsten, tin, silica, alumina and zirconium.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby\&#39;s medical history/physical exam, and the results of the genomic sequencing report.
An improved informed consent system and method is disclosed. The system comprises a visual component, an auditory component, and a textual component. The visual component consists of a visual representation of the surgery, preferably in three-dimensional form. The auditory component consists of a narration integral with the visual component that explains the visual representation of the surgery. The textual component consists of a summary of each complication associated with the surgery. The system includes an input mechanism for inputting an acknowledgment of each complication, as well as each complication encountered by the patient during the surgery, and a storage mechanism for electronically storing the patient&#39;s acknowledgment of each complication. The visual, auditory, and textual components are preferably integrally combined to form a single informed consent system.
NEW MATERIAL:An indane derivative of formulaI(R&lt;1&gt; and R&lt;3&gt; are H or lower  alkyl; R&lt;2&gt; is H, lower alkyl or lower aralkyl) or a salt thereof. EXAMPLE:N-(1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl-N-(2-indanyl)glycine hydrochloride. USE:Useful as a diagnostic agent, preventing agent or remedy for hypertension, having inhibitory action on antiotensin converting enzymes and on bradykinin hydrolytic enzymes (kininase) with low toxicity and improved stability, and easily absorbable even by the oral administration. PROCESS:A compound of formula II is condensed with a compound of formula III under reducing conditions to give the compound of formulaI. The reduction or electrolytic reduction with a metallic hydride compound may be cited as the reducing conditions. The reaction is carried out usually in the presence of water or an organic solvent, preferably at -20-+100 deg.C.
Acetylated cardiotonic glucosides are produced by reacting the glucoside with an alkyl orthoacetate and submitting the resulting cyclic orthoacetate to partial saponification. The intermediate cyclic orthoacetate may be isolated and/or other free OH gps. acetylated if desired. This process enables acetyl gps. to be introduced into desired positions on the pyrannoside radical of the glocoside. Preferred products are alpha-digoxin, alpha-digitoxin, and 2&#39;-acetyl-proscillaridin. The products are of value in the treatment of cardiac insufficiency. They are more readily absorbed than the parent glucosides.
PROBLEM TO BE SOLVED: To provide a new compound consisting of a separated polypeptide containing an amino acid sequence having high identity to a specific amino acid sequence and useful e.g. for the treatment and diagnosis of hypercardia, cardiac failure, ischemia, arrhythmia, hypertension, atherosclerosis, cancer, etc. SOLUTION: This new polypeptide is a separated polypeptide containing an amino acid sequence having identity of &gt;=70% to the amino acid sequence of the formula I and a separated polypeptide containing an amino acid sequence having identity of &gt;=70% to the amino acid sequence of the formula II. It is useful e.g. for the treatment and diagnostic assay of hypercardia, cardiac failure, ischemia, arrhythmia, hypertension, atherosclerosis, restenosis, chronic and acute inflammation, cerebral attack, rheumatoid arthritis, disseminated sclerosis, intestinal disease, diabetes, cancer, etc. The polypeptide can be produced from a cDNA library originated from mRNA in a cell such as human brain, heart or fetus dura cell by preparing a gene from the library by standard cloning and screening technique and expressing the gene in a host cell by recombination technique.
The invention provides &#39;astragalus notoginseng root body resistance strengthening pills&#39; serving as a Chinese medicinal composition. The composition contains honey-fried astragalus, fortune&#39;s drynaria rhizome, garter snake, notoginseng root, honey-fried frankincense, honey-fried myrrh and prepared rehmannia root. The invention also relates to application of the Chinese medicinal composition to strengthening body resistance to eliminate pathogenic factors, dispelling wind, eliminating dampness, promoting blood circulation and relieving pain and application of the Chinese medicinal composition to preparation of medicines for treating diseases such as blood stasis pain of paralysis and tuberculosis and the like. Experimental results indicate that according to the Chinese medicinal composition with different ratios, common Chinese medicinal materials are subjected to compatibility according to the theory of traditional Chinese medical science, so that the Chinese medicinal composition has the effects of strengthening body resistance to consolidate constitution and promoting blood circulation to remove blood stasis, and is used for treating the blood stasis pain of paralysis and tuberculosis caused by body resistance deficiency and evil convergence. Seven Chinese medicines in the Chinese medicinal composition are wide in medicinal sources, readily available, low in cost and reasonable in compatibility, and a formula is simple, so the Chinese medicinal composition has the characteristics of definite curative effect, no toxic or side effects, controllable quality standard and easiness in absorption. A method for preparing the Chinese medicinal composition is simple, and the Chinese medicines are prepared into the pills, so that bad smell of the medicines is covered, the pills are convenient to carry, treatment is ensured, and the Chinese medicinal composition can be taken for a long time.